Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy
Education Initiative in Neurology

  • Multiple Sclerosis — Case Study: Treatment of a Patient With Relapsing MS During the Covid-19 Pandemic – @Point of Care Chapter
  • In patients with relapsing forms of multiple sclerosis (MS), there may be underlying progression in the absence of relapse activity. Choosing to initiate treatment with a high-efficacy disease-modifying therapy (DMT) is one strategy to address such accumulation of disability. In addition, in the context of a ... more >>
    R. Bermel, MD
  • Alzheimer's Disease — Alzheimer’s Disease: From Diagnosis to Treatment, Change Is Coming – BreakingMED
  • Recent Alzheimer’s disease research has poised the field for a watershed period in diagnosis and treatment, which may begin as early as this year. This shifting clinical landscape in Alzheimer’s research includes blood tests to identify possible biomarkers, the first FDA-approved tau PET ligand, and the ... more >>
    V. Abramson, MD
  • Stroke Prevention — Patient With Atrial Fibrillation at High Risk for Stroke or Thromboembolism Who Underwent Percutaneous Intervention for Acute Coronary Syndrome – Webcast
  • Patients with atrial fibrillation who undergo percutaneous intervention to treat acute coronary syndrome need highly personalized monitoring and treatment decision-making to manage the ongoing risks of stroke or thromboembolism, bleeding, and recurrent cardiac ischemic event following percutaneous ... more >>
  • Neurology Care Considerations — Neurology Journal Club – Podcast
  • How has the Covid-19 pandemic affected amyotrophic lateral sclerosis (ALS) patients? In this Journal Club podcast our faculty discusses several papers showing how the virus may affect ALS patients as well as what they are seeing in their clinics.
    R. Bedlack, Jr, MD, PhD, FAAN
  • Multiple Sclerosis — Lateral Tx Switches in Patients with Clinically Stable MS Do Not Increase Risks of Relapse, Disability – BreakingMED
  • As oral first-line therapies for multiple sclerosis (MS) become more readily available, drugs such as dimethyl fumarate or teriflunomide have become popular choices as first-line therapy or as an alternative for patients already on platform injectable therapies. In this article, researchers assess the safety ... more >>
    V. Abramson, MD
  • Multiple Sclerosis — Case Study: Special Considerations Regarding Covid-19 for a Patient With Multiple Sclerosis – @Point of Care Chapter
  • In the current era in which a highly infectious disease is present in the general population, it is important to consider the role of immunosuppression from disease-modifying therapies (DMTs) in choosing whether to initiate, change, or suspend treatment in patients with multiple sclerosis (MS). In patients ... more >>
    E. Williamson, MD
  • Multiple Sclerosis — MS Disease-Modifying Therapy Shows Reduced Disability Accrual Over 15 Years – BreakingMED
  • Findings culled from an analysis of data from 14,717 patients in the MSBase registry provide some long-needed answers to questions about the long-term effects of disease-modifying therapy in patients with relapsing-remitting disease—and those answers are encouraging.
    V. Abramson, MD
  • Multiple Sclerosis — MS: Eyes on the Horizon – Podcast
  • With more than 20 disease-modifying therapies for multiple sclerosis (MS), there are still more in development. Our faculty look at what is still needed and emerging MS therapies. Moreover, they discuss how these new agents will impact clinical decision making.
  • Multiple Sclerosis — Switching Tracks in MS, Timing and Direction – Podcast
  • With the many disease-modifying therapies now available for multiple sclerosis, there are times when patients may need treatment escalated or even a lateral switch to another therapy. In this podcast, our faculty discuss assessing clinical response to these therapies and when a switch may be warranted.
    P. Coyle, MD
    J. Rinker, MD
  • Multiple Sclerosis — MS: Alike But Not Alike – Podcast
  • Are the fumarates for the treatment of multiple sclerosis the same? Diroximel fumarate is the newest fumarate on the block. How does it compare with monomethyl fumarate and dimethyl fumarate? Our faculty discuss the differences and similarities of the treatments, side effects, and when to prescribe these ... more >>
    P. Coyle, MD
    J. Rinker, MD
  • State of the Science: Multiple Sclerosis Innovations
  • State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from ... more >>
    A. Cross, MD
    P. Peck, Editor-in-Chief
  • Clinical Context: Stroke Prevention in Atrial Fibrilation
  • Clinical Context: Stroke Prevention in
    Atrial Fibrillation
    is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.

    The curriculum includes:
    • 6 case studies
    • MedPage Today meeting
    ...
    more >>
    C. Yancy, MD, MSc
  • Neurology Mastery in Multiple Sclerosis
  • Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. ... more >>
    J. Bowen, MD
  • Clinical Context: Migraine
  • Clinical Context: Migraine is designed to provide up-to-date information on current and emerging management strategies based on the most up-to-date evidence-based medicine and clinical trial results in migraine. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that ... more >>
    D. Friedman, MD, MPH
  • Clinical Context: Multiple Sclerosis

  • Clinical Context: Multiple Sclerosis is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of multiple sclerosis.

    The curriculum includes four case studies at the point of care and MedPage ...
    more >>
    P. Coyle, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Stroke Prevention in Atrial Fibrillation and VTE @Point of Care
  • Stroke Prevention in Atrial Fibrillation and VTE @Point of Care is a clinical decision-making tool that provides a streamlined, comprehensive mobile reference for clinicians to obtain information on the diagnosis, treatment and management of Atrial Fibrillation and VTE. It is made up of a progressive series ... more >>
    S. Connolly, MD, FRCPC
  • Parkinson's Disease @Point of Care
  • From 2005 to 2030, the number of patients with Parkinson’s disease is expected to double. Caroline M. Tanner, MD, PhD provides an overview of the epidemiology of Parkinson’s disease and its associated morbidity in this subchapter of the Parkinson’s Disease @POC program.
    R. Hauser, MD, MBA
  • Multiple Sclerosis @Point of Care
  • MS @Point of Care is a clinical decision support platform that provides comprehensive information on the diagnosis, treatment and management of multiple sclerosis, made up of a progressive series of chapters and other learning tools. It provides multimedia offerings, and contextual expansion of content ... more >>
    B. Cohen, MD
    P. Coyle, MD
  • Stroke Prevention — Patient With Atrial Fibrillation at High Risk for Stroke or Thromboembolism Who Underwent Percutaneous Intervention for Acute Coronary Syndrome – Webcast
  • Patients with atrial fibrillation who undergo percutaneous intervention to treat acute coronary syndrome need highly personalized monitoring and treatment decision-making to manage the ongoing risks of stroke or thromboembolism, bleeding, and recurrent cardiac ischemic event following percutaneous ... more >>
  • Neurology Care Considerations — Neurology Journal Club – Podcast
  • How has the Covid-19 pandemic affected amyotrophic lateral sclerosis (ALS) patients? In this Journal Club podcast our faculty discusses several papers showing how the virus may affect ALS patients as well as what they are seeing in their clinics.
    R. Bedlack, Jr, MD, PhD, FAAN
  • Multiple Sclerosis — MS: Eyes on the Horizon – Podcast
  • With more than 20 disease-modifying therapies for multiple sclerosis (MS), there are still more in development. Our faculty look at what is still needed and emerging MS therapies. Moreover, they discuss how these new agents will impact clinical decision making.
  • Multiple Sclerosis — Switching Tracks in MS, Timing and Direction – Podcast
  • With the many disease-modifying therapies now available for multiple sclerosis, there are times when patients may need treatment escalated or even a lateral switch to another therapy. In this podcast, our faculty discuss assessing clinical response to these therapies and when a switch may be warranted.
    P. Coyle, MD
    J. Rinker, MD
  • Multiple Sclerosis — MS: Alike But Not Alike – Podcast
  • Are the fumarates for the treatment of multiple sclerosis the same? Diroximel fumarate is the newest fumarate on the block. How does it compare with monomethyl fumarate and dimethyl fumarate? Our faculty discuss the differences and similarities of the treatments, side effects, and when to prescribe these ... more >>
    P. Coyle, MD
    J. Rinker, MD
  • Multiple Sclerosis — Close to the Mark on secondary Progressive MS – Podcast
  • What is the current evidence for using disease-modifying therapies (DMTs) for secondary progressive MS (SPMS)? Our faculty discusses the difficulty in diagnosing SPMS and the current treatment options.
    R. Bermel, MD
    F. Lublin, MD
  • Multiple Sclerosis — MS: Comparing Notes on S1P Receptor Modulators – Podcast
  • Fingolimod sphingosine-1-phosphate receptor (S1PR) modulators was the first S1PR modulator on the market for the treatment of multiple sclerosis. Now there are several second-generation S1PR modulators available—siponimod, ozanimod, and poised for FDA approval, ponesimod. Our faculty discusses these therapies ... more >>
    P. Coyle, MD
    J. Rinker, MD
  • Multiple Sclerosis — Crystal Gazing in MS – Podcast
  • Diagnosing multiple sclerosis (MS), determining when to begin first-line treatment and then prognosticating how patients will do over the course of their disease often requires a crystal ball. In this podcast Drs. Lublin and Bermel discuss diagnosing MS, the evolution of and choosing treatment options, and ... more >>
    R. Bermel, MD
    F. Lublin, MD
  • ALS — Special Considerations in Covid-19 in Neurology: – Webcast
  • The World Health Organization declared the novel coronavirus (SARS-CoV 2) outbreak a pandemic on March 11, 2020. As the year 2020 draws to a close, long-awaited vaccines are awaiting approval from the FDA, which has already issued Emergency Use Authorizations for monoclonal antibody therapies as well as the ... more >>
    R. Bedlack, Jr, MD, PhD, FAAN
  • Parkinson's Disease — Journal Club Podcast in Neurology – Podcast
  • In this Journal Club podcast our experts discuss a paper published in the Journal of Clinical Medicine that looked at the impact of Covid-19 on patients with Parkinson’s disease—physically, emotionally, and how they are keeping up with their treatments.
    R. Hauser, MD, MBA
  • Multiple Sclerosis — Managing RRMS Patient who Converted to SPMS – Case Study
  • This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — Managing Highly Active Disease in an RRMS Patient with Worsening on Initial Treatment – Case Study
  • This case illustrates the treatment strategy employed for a RRMS patient who has high MS disease activity despite adherence to first-line injectable disease-modifying therapy. It highlights switching strategies that can be considered for such patients, and reviews safety and efficacy data for approved high- ... more >>
    P. Repovic, MD
  • Multiple Sclerosis — RRMS Patient with Active On-Treatment Disease Considering a Switch to a Selective Oral S1P Inhibitor – Case Study
  • In this case, the diagnosis and initial treatment of a patient with relapsing multiple sclerosis (MS) is reviewed. This illustrates the considerations that occur when a patient has a clinical relapse while on disease-modifying therapy and highlights available and emerging oral therapies for the treatment of ... more >>
    C. Azevedo, MD, MPH
  • Multiple Sclerosis — Case Study: Misdiagnosis in MS – Case Study
  • The 2017 revisions to the McDonald criteria have refined the diagnosis of multiple sclerosis (MS). However, these criteria must only be applied to patients with symptoms typical of demyelination. In addition, there must be "no better explanation." This case follows the skillful navigation of diagnosis in a 56 ... more >>
    A. Solomon, MD
  • Multiple Sclerosis — Risk-Averse RRMS Patient With a Preference for an Oral DMT – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) who has a clinical relapse on his first disease-modifying therapy. It illustrates considerations when switching medications, including patient preference for therapeutic delivery, and ... more >>
    J. Bowen, MD
  • Multiple Sclerosis — Case Study: Patient With Secondary-Progressive MS and Active Disease – Case Study
  • This case study follows a 39-year-old man who developed relapsing-remitting multiple sclerosis (MS) when he was 34. He is being treated with an oral agent for relapsing MS; however he has since advanced to secondary-progressive MS (SPMS) and shows signs of active disease radiographically. New treatment ... more >>
    E. Williamson, MD
  • Multiple Sclerosis — Patient with Active Relapsing MS at High Risk for PML – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) that is following an aggressive clinical course. It illustrates the considerations that should occur when initiating and switching disease modifying therapies (DMTs), as well as highlighting ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — An African American Patient with Increasing Symptoms: Managing a Newly Diagnosed Patient with PPMS – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with primary progressive multiple sclerosis (PPMS). It illustrates the considerations involved in selection of treatment for patients with progressive forms of MS, as well as highlighting the natural course of progressive disease and the ... more >>
    J. Rinker, MD
  • Multiple Sclerosis — A Patient with RRMS Who Experiences Breakthrough Disease on Two Disease-Modifying Therapies – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing-remitting multiple sclerosis (RRMS) who has breakthrough disease activity on her first disease-modifying therapy (DMT) and switches to a different class of DMT. After doing well on her second DMT for awhile, she experiences ... more >>
    J. Bowen, MD
  • Multiple Sclerosis — RRMS Patient With Newly Diagnosed SPMS After Experiencing Increased Disability and Disease Progression – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing multiple sclerosis (MS) who has been treated with two disease modifying treatments (DMTs) and now presents with symptoms of secondary progressive MS (SPMS). The activity highlights how environmental factors and comorbidities ... more >>
    P. Coyle, MD

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information